US buyout house Madison Dearborn Partners is reportedly nearing a $1.5bn-plus deal to buy private equity and venture capital-backed drug business Ikaria.
The company, which boasts investors including New Mountain Capital, ARCH Venture Partners and Venrock Associates, could be sold by the end of the week according to Reuters, which cited people familiar with the matter.
It said fellow buyout firms GTCR and American Securities were also interested in the business, which makes a drug to treat newborn babies for breathing difficulties among other things.
New Mountain led the creation of Ikaria in 2007 when it and fellow investors merged a biotech company with the same name with German industrial gas producer Linde’s INO Therapeutics in a $670m deal, Reuters added.
Copyright © 2013 AltAssets